How Will Construction Firms Build on a Rough 2020?

Most employees found themselves working remotely since the beginning of the pandemic. However, that hasn’t been the case for those in the construction industry, as their work hinges on the physical work they do on a day-to-day basis.

How have construction companies managed so far, and what can they expect for 2021 and beyond? Daniel Litwin, the Voice of B2B, dives into the impacts of COVID-19 on the construction industry and how it’s navigating the new health and safety risks in the workplace.

In order to do so, he met with David Patrick, the president of Downes Construction Company, as well as Rachel Walla, an industrial safety and health consultant at Ally Safety, to get their insights on the topic.

“We’re going to see a lot more in the multi-family housing market,” predicted Patrick. “There’s a lot of money on the sidelines that’s willing to be invested in this. I think that market rate and lower-income housing is going to be a popular topic of discussion.”

Walla’s experience on the health and safety side of the industry offered another perspective. “It’s been really difficult for businesses to manage how they approach COVID-19,” she noted. “We jumped into this without any real regulations, so although some companies had certain pandemic response plans, they were pretty limited and we didn’t really have them in place where we were ready to enact them.”

However, they are both optimistic — although a little cautious — for the future.

“What we’re seeing is that there were some stops and starts for 2020,” said Walla. “2021 seems to have a more stable outlook overall for the projects, but there’s still uncertainty.”

Patrick echoed her sentiment: “Here in New England, we certainly have seen a slowdown from 2020, but going into 2021, I think everyone’s a little more comfortable with what’s going on in the construction marketplace.”

KEY POINTS:

  1. In 2020, commercial and office real estate development took a hit in many regions.
  2. OSHA citations related to COVID hit the $3.9 million mark in early January 2020.
  3. Moving forward, employers will focus on vaccination education efforts rather than pushing for vaccinations themselves.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

AMAG Technology
AMAG Technology: Control, Reliability, and Customer-First Supply Chain Excellence
April 2, 2025

At AMAG Technology, being customer-obsessed goes beyond a mindset—it’s built into every part of the operation. One of the company’s greatest strengths lies in its ability to manufacture its own products, offering a level of supply chain control that few competitors can match. Allan Price, Head of Global Supply Chain at AMAG, emphasizes how this…

Read More
visitor management solution
Reinventing Visitor Management Solution with Symmetry GUEST
April 2, 2025

In an age where speed and security are paramount, the traditional paper logbook is becoming a relic of the past. AMAG Technology’s Symmetry Guest system offers a modern, digital solution that redefines the way organizations welcome and manage visitors. Gone are the days of long lines and confusion at the front desk—Symmetry Guest empowers hosts…

Read More
AMAG
Driven by Customers, Defined by Innovation: Inside AMAG’s Customer-Obsessed Approach
April 2, 2025

AMAG Technology continues to strengthen its customer-obsessed culture by actively listening to both internal and external voices. As shared by Kyle Gordon, Executive Vice President of Global Sales, Marketing, & Commercial Excellence, the company is focused on improving processes, responding with speed, and driving innovation—while honoring its legacy and delivering unique value within the industry.

Read More
biotech
Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation
April 2, 2025

As biotech innovation accelerates, small and mid-size pharmaceutical companies are becoming key players in bringing new treatments to market. Yet many of these organizations face steep challenges when navigating clinical trial design, regulatory approval, and data integrity. According to a McKinsey Global Institute report, industries like biotech could help generate up to $50 trillion…

Read More